Voyager Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2013)

Organization Overview

First Clinical Trial
2013
NCT01973543
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Voyager Therapeutics | Voyager Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

vy-aadc02 (1 trial)

Drugs in Phase 1 Trials (2)

vy-aadc01 (2 trials)

VY-HTT01 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Basal Ganglia Diseases (Phase 1)

Brain Diseases (Phase 1)

Central Nervous System Diseases (Phase 1)

Disease (Phase 1)

Movement Disorders (Phase 1)

Nervous System Diseases (Phase 1)

Neurodegenerative Diseases (Phase 1)

Parkinson Disease (Phase 2)

Parkinsonian Disorders (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3